Choose Your Country or Region

Cisplatin

Name: Cisplatin
Brand: Selleck Chemicals
SKU: S1166
Rating: 5 (700 reviews)

Synonyms: NSC 119875, Cisplatinum, cis-diamminedichloroplatinum II, CDDP, cis DDP, DDP

Catalog No.S1166 Purity: 99.84%

Cisplatin is an inorganic platinum complex, which is able to inhibit DNA synthesis by conforming DNA adducts in tumor cells. Cisplatin activates ferroptosis and induces autophagy.Solutions are unstable and should be fresh-prepared.DMSO is not recommended to dissolve platinum-based drugs, which can easily lead to drug inactivation.

Cisplatin Chemical Structure

CAS: 15663-27-1

Selleck's Cisplatin has been cited by 700 publications

Purity & Quality Control

Batch: Purity: 99.84%

99.84

Products often used together with Cisplatin

Ceralasertib (AZD6738)

Explores the combined effect that potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo

Vendetti FP, et al. Oncotarget. 2015 Dec 29; 6(42): 44289–44305.

Olaparib (AZD2281)

Cisplatin in combination with olaparib exhibits the significant synergistic effect in inhibiting the proliferation of the ovarian cancer cells.

Gao J, et al. Exp Ther Med. 2021;22(3):935.

Berzosertib (VE-822)

Berzosertib (VX-970), when given in combination with cisplatin, enhances the efficacy of cisplatin in patient-derived lung tumour xenografts.

Hall AB, et al. Oncotarget. 2014;5(14):5674-5685.

Durvalumab (anti-PD-L1)

Cisplatin in combination with durvalumab can show a synergistic effect in small-cell lung cancer (SCLC).

Tsvetkova D, et al. Molecules. 2022;27(8):2466. Published 2022 Apr 11.

Elimusertib (BAY-1895344)

Combination treatment with BAY 1895344 and cisplatin achieved strong synergistic activity on the proliferation of human HT-29 colorectal cancer cells in vitro.

Wengner AM, et al. Mol Cancer Ther. 2020 Jan;19(1):26-38.

Other DNA/RNA Synthesis Products

Related compound libraries

Choose Selective DNA/RNA Synthesis Inhibitors

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
Human osteosarcoma cells (HOS, 143B, U2OS and MG‑63)	Cell cycle analysis	2 μM	48 h	Cisplatin treatment markedly increased the G2/M population in all cell lines.	31059083
OVC cells (A2780, TOV-112D, and cis-A2780)	Cell Cytotoxicity Assay	0.5, 1, 2.5, 5, 10, 20, and 50 μM	48 h	Combination of cisplatin and MEK inhibitor cobimetinib (10 nM) enhances cell death in three ovarian cancer cell lines (A2780, TOV-112D, and cis-A2780).	31057611
HCC cell lines HepG2 and Huh7	Cell viability assay	0-30 μM	48 h	CD133+ HCC cells exhibit resistance to cisplatin.	31056532
Saos-2 cells				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	29435139
OHS-50 cells				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	29435139
SK-N-MC cells				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	29435139
Click to View More Cell Line Experimental Data

Biological Activity

Description

Features

One of the most widely used and most potent chemotherapeutic agents. This product is not recommended to be dissolved in dimethylsulfoxide (DMSO).^[7]

Targets

DNA synthesis ^[1]
(Tumor cells)

In vitro
In vitro	Cisplatin induces cytotoxic by interaction with DNA to form DNA adducts which activate several signal transduction pathways, including Erk, p53, p73, and MAPK, which culminates in the activation of apoptosis. ^[1] Cisplatin (30 μM) treated for 6 h induces an apparent activation of Erk in HeLa cells, which is sustained over the following 14 h period. Cisplatin also shows an effective antineoplastic activity by inducing tumor cells death^[2]. Cisplatin displays ability to cause renal proximal tubular cell (RPTC) apoptosis, causing cell shrinkage, a 50-fold increase in caspase 3 activity, a 4-fold increase in phosphatidylserine externalization, and 5- and 15-fold increases in chromatin condensation and DNA hypoploidy, respectively. ^[4] Cisplatin (800 μM) causes typical features of necrosis of RPTC after treatment for 4 hr. ^[5]
Cell Research	Cell lines	Leukemia L1210/0 cells
	Concentrations	7 μg/mL
	Incubation Time	2 hours
	Method	L1210/0 cells are maintained in an exponential suspension culture at 37 ℃ in a humidified atmosphere of 5% CO₂ in McCoy's medium 5a (modified), supplemented with 15% calfserum, and Fungizone. L1210/0 cells are incubated in Cisplatin (7 μg/mL) for 2 hr at 37 ℃. To measure growth inhibition, the cells are centrifuged, washed once, resuspended in fresh medium at 30 × 10³ to 50 × 10³ cells/mL, and incubated for 3 days. Cell numbers are determined on a Coulter Counter. An aliquot of cells is diluted with an equal volume of 0.4% trypan blue. Viability is recorded as the percentage of cells that has excluded trypan blue. Cells incubated with Cisplatin as above are also diluted into 0.1% agar and allowed to grow for 2 weeks when colonies are counted.
Experimental Result Images	Methods	Biomarkers	Images	PMID
	Western blot	ATF3 FEN1 PD-L1 / p-MEK / MEK / p-STAT3 / STAT3 LC3B-I / LC3B-II / Beclin-1 p-AMPK / AMPK / p-mTOR / mTOR		20651982
	Immunofluorescence	H2A.X / RPA γ-H2A.X / 53BP1 N-cadherin / E-cadherin / Vimentin LC3B		28993682
	Growth inhibition assay	Cell viability		26062553

In Vivo
In vivo	Cisplatin has been demonstrated to be efficient in regression tumor growth in a wide variety of animal tumors models, including head and neck cancer xenografts, cervical squamous carcinoma xenografts, testicular carcinoma xenografts, ovarian cancer xenografts, breast carcinoma xenografts, colonic carcinoma, heterotransplanted hepatoblastoma, and so on. Cisplatin (5 mg/kg) given weekly i.v. at the day 1 and 7 induces a tumor growth inhibition (GI) of 77.5% and 85.1% of the serous xenografts Ov.Ri(C) and OVCAR-3, respectively. ^[6]
Animal Research	Animal Models	Female NMRI/Cpb (nuinu) mice
	Dosages	5 mg/kg
	Administration	i.v.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2024-01-11)
NCT04915183	Not yet recruiting	Hearing Loss\|Head and Neck Cancer	National Institute on Deafness and Other Communication Disorders (NIDCD)\|National Institutes of Health Clinical Center (CC)	January 12 2024	Phase 3
NCT06086288	Not yet recruiting	Merkel Cell Carcinoma	Fondazione IRCCS Istituto Nazionale dei Tumori Milano	November 2023	Phase 2
NCT04402593	Withdrawn	Relapsed Germ Cell Cancer\|Cisplatin Induced Tinnitus	Indiana University	September 2023	Not Applicable
NCT05946577	Not yet recruiting	Head Cancer\|Neck Cancer	Assistance Publique - Hôpitaux de Paris	July 2023	--

References

+ Expand

Chemical lnformation & Solubility

Molecular Weight	300.05	Formula	Cl₂H₆N₂Pt
CAS No.	15663-27-1	SDF	Download Cisplatin SDF
Smiles	[NH2-].[NH2-].Cl[Pt+2]Cl
Storage (From the date of receipt)	2 years 4°C(in the dark) powder	Solutions are unstable. Prepare fresh or purchase small, pre-packaged sizes. Repackage upon receipt.

In vitro
Batch:

DMF : 15 mg/mL

Water : Insoluble

Ethanol : Insoluble

Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.

In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Frequently Asked Questions

Question 1:
What is the appropriate concentration of DMF for cell culture and animal study?

Answer:
It depends on the cell type. The final concentration of DMF should be better limited to less than 0.1% if possible, or below 1%. Using saline as a vehicle for cisplatin at up to 3mg/ml is recommended. it's a suspension and can be administrated via oral gavage.

DNA/RNA Synthesis Signaling Pathway Map

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):